DOD Reconstructive Transplant, Idea Discovery Award | HT9425 23 RTRP IDA

Opportunity Information: Apply for HT9425 23 RTRP IDA

The FY23 Department of Defense Reconstructive Transplant Research Program (RTRP) Idea Discovery Award (Funding Opportunity Number: HT9425 23 RTRP IDA) is a discretionary research funding opportunity run through the Department of Defense, Department of the Army, U.S. Army Medical Research Acquisition Activity (USAMRAA). It is designed to back early, exploratory work in reconstructive transplant, with a clear preference for ideas that are genuinely new, not yet proven, and somewhat risky, but with the potential to open up entirely new directions if they succeed. The core expectation is that the project will produce solid, convincing data that can serve as a launchpad for larger, follow-on studies rather than delivering a final, fully translated solution in a single step.

A defining feature of this mechanism is its emphasis on innovation. Applications are expected to bring forward concepts, theories, paradigms, or methods that either introduce a new way of thinking, challenge an existing assumption, or tackle a persistent problem from an unfamiliar angle. The program is explicit that incremental studies will not be funded under this award. In other words, a proposal that simply extends prior published work, adds another experimental condition, or represents the next logical step of an ongoing research line is unlikely to be viewed as responsive. If an applicant draws on established findings from solid organ transplant research, they must clearly explain what makes the approach novel in reconstructive transplant or vascularized composite allotransplantation (VCA) and why the VCA setting could reasonably lead to different outcomes, require confirmation, or provide unique mechanistic insight.

Beyond novelty, the program expects a well-formed scientific argument. Proposals should present a testable hypothesis and a coherent rationale supported by a strong study design. Even though the research is supposed to be untested and exploratory, preliminary or published data are still required to justify the premise and demonstrate feasibility. The intent is to strike a balance: the idea should be bold and new, but the application should still show enough grounding to convince reviewers the work can be executed and will generate interpretable results.

Impact is another central review priority. Projects must address at least one of the FY23 RTRP Idea Discovery Award Focus Areas (not listed in the provided text, but explicitly required). Applicants are expected to spell out what the work will produce, whether that is a knowledge product (for example, mechanistic insight, proof-of-concept evidence, or a validated method) or a material product (such as a tool, assay, platform, or dataset). Just as importantly, the proposal should explain how those near-term outputs could translate into longer-term gains for the reconstructive transplant field, such as enabling new research avenues, informing future therapeutic strategies, or reshaping how key problems are approached.

Military relevance is required rather than optional. The research must be clearly tied to the health care needs of Service Members and/or Veterans recovering from traumatic injury, and the opportunity also recognizes the broader ecosystem around those patients, including family members, caregivers, and clinicians, as well as benefits to the general public. While not mandatory, collaboration with military researchers and clinicians is encouraged and can help demonstrate that the work is aligned with real-world needs within military medicine and rehabilitation.

From a regulatory and project design standpoint, the award is intentionally positioned as a preliminary investigation mechanism, which strongly limits human research activities. Projects involving human subjects or anatomical substances are generally not supported unless they qualify for exemption under 32 CFR 219.104(d) or are eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110. Studies that do not meet exempt or expedited criteria will be administratively withdrawn, meaning they are removed from consideration and will not be funded. Consistent with that, clinical trials are not allowed. The opportunity uses the standard definition of a clinical trial: any study where one or more human subjects are prospectively assigned to one or more interventions (including placebo or controls) to evaluate effects on biomedical or behavioral health-related outcomes. Practically speaking, this pushes applicants toward preclinical, in vitro, computational, or other non-clinical approaches that can still generate strong foundational data.

Administratively, the opportunity is open to an unrestricted applicant pool (broad eligibility across entity types, subject to any additional eligibility clarifications in the full announcement). Awards may be made as grants or cooperative agreements. The CFDA number listed is 12.420. The opportunity was created on June 5, 2023, with an original closing date of October 11, 2023. The listing indicates an expected five awards. The published award ceiling is shown as 0, which typically signals that a specific maximum dollar amount was not provided in this summarized record and would need to be confirmed in the full funding announcement or associated program documentation.

Overall, this funding mechanism is best understood as DoD support for bold, early-stage reconstructive transplant ideas that are scientifically defensible, clearly aligned with military health needs, and capable of producing high-quality proof-of-concept data, while staying away from non-exempt or non-expedited human subjects research and avoiding any clinical trial design.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD Reconstructive Transplant, Idea Discovery Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Jun 05, 2023.
• Applicants must submit their applications by Oct 11, 2023. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 5 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for HT9425 23 RTRP IDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: